AB-BIOTICS, a Kaneka company, will exhibit at this year’s Vitafoods Europe to showcase scientific findings on its latest probiotic solutions for women’s health and sports nutrition.
Managing the menopause
The company’s R&D manager, Dr Marta Pérez, will be delivering a session at the Biotics Theatre, K232, on 15th May, on the role probiotics can play in managing symptoms of menopause and how AB-BIOTICS translates this into today’s offerings.
Shining a spotlight on an in-demand and under-researched therapeutic area in women’s health, AB-BIOTICS will highlight the latest research on its solution for managing menopause symptoms, commercially known as Gyntima Menopause.
Containing a blend of strains L. plantarum KABP 051, L. brevis KABP 052 and P. acidilactici KABP 021, the probiotic blend provides women with a safe and effective solution for managing all stages of menopause by modulating oestrogen levels in the gut.1
The hormonal fluctuations which occur during menopause have been known to affect women’s physical and mental health. In the session titled ‘Understanding Menopause’, Dr Marta Pérez will discuss AB-BIOTICS’ clinical trial which investigated the mechanism of action and capacity of a proprietary probiotic blend to modulate serum oestrogen levels.
Probiotics for vaginal health
At the event, experts from AB-BIOTICS will also discuss the relevant clinical research surrounding Gyntima - the company’s vaginal health portfolio.
This includes Gyntima Cyscare for protecting the urinary tract from infections and Gyntima Balance, for the restoration of vaginal microbiota.
Gyntima Re-Balance, a medical device targeting vaginal infections such as candidiasis and bacterial vaginosis, will also be on display this year.
Probiotics for elite athletes
Alongside its solutions for women’s health, AB-BIOTICS will showcase the preliminary results of the latest clinical trial on its i3.1 product which shows potential to support elite athletes affected by digestive issues that often occur from undertaking high-intensity sport.
The probiotic i3.1, containing strains L. plantarum KABPT 022, L. plantarum KABP 023 and P. acidilactici KABP 021, has been shown to reduce digestive complaints associated with intense physical exercise and could facilitate the recovery of gastrointestinal function post-exercise.2
Probiotics for cardiovascular health
Attendees will also hear about the findings of a recently-published study focused on probiotics for cardiovascular health.3 L. plantarum strains KABP 011, KABP 012 and KABP 013, marketed as AB-LIFE, have been shown to lower cholesterol by impacting low-density lipoprotein (LDL) particle size and apoliproteins – relevant biomarkers in atherosclerosis4.
References
1 Honda et al (submitted). Supplementation with a probiotic formula having β-glucuronidase activity modulates serum estrogen levels in healthy peri- and postmenopausal women.
2 AB-BIOTICS unpublished study 2024
3 Padro T, de Santisteban V, Huedo P, et al. Lactiplantibacillus plantarum strains KABP011, KABP012 and KABP013 modulate bile acids and cholesterol metabolism in humans. Cardiovasc Res
4 Kerlikowsky et al. Distinct Microbial Taxa Are Associated with LDL-Cholesterol Reduction after 12 Weeks of Lactobacillus plantarum Intake in Mild Hypercholesterolemia: Results of a Randomized Controlled Study. Probiotics and Antimicrobial Proteins, 2023.
